Prospera

New publication shows that Prospera-guided care helped >75% of low-risk patients safely avoid routine transbronchial biopsies performed at 9 months AUSTIN, Texas, January 26, 2026–(BUSINESS WIRE)–Natera, Inc. (NASDAQ: NTRA), a …

David Ross, Senior Medical Director, Lung Transplantation and Molecular Diagnostics at Natera, shared a post on LinkedIn: “Prospera Lung test (donor-derived cell-free DNA) surveillance permits a safe reduction in protocol …